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From Human Peripheral Blood Progenitors 
By Sudhir Sekhsaria and Harry L. Malech 
Peripheral  blood hematopoietic progenitors (PBHP) are ca- 
pable of colony growth in  vitro. The effect of stem cell factor 
(SCF), interleukin-6 (IL-6). and basic fibroblast growth  factor 
(bFGF) on myeloid colony proliferation of PBHP was deter- 
mined. PBHP purified by positive selection with CD34- 
specific antibody were plated in semisolid agarose with 
reported plateau doses of interleukin-3 (IL-3). granulocyte- 
macrophage  colony-stimulating  factor  (GM-CSF),  and 
granulocyte colony-stimulating factor (G-CSF) to enhance 
myeloid colony growth. Experiments  then were done to  ex- 
amine colony growth in response  to  SCF or with SCF and 
bFGF and/or IL6. SCF  alone in the absence of any other 
growth factors did not support colony growth.  SCF  at a 
determined optimum concentration of 100  ng/mL added  to 
the combination of IL-3, GM-CSF, and G-CSF enhanced 
colony growth and size relative to proliferation in response 
to  the latter three factors alone (from 78 to 188  total col- 
T IS ESTABLISHED that normal peripheral blood con-  I  tains a small number of circulating noncycling progenitor 
cells.’s2  In contrast to bone marrow (BM), peripheral blood 
hematopoietic  progenitors  (PBHP)  are  relatively  free  of 
stromal microenvironmental  interactions. PBHP may rep- 
resent a cell population with growth and functional charac- 
teristics distinct from BM  precursor^.^ Furthermore, there is 
increasing interest in PBHP as  an alternate and/or supplement 
to BM  for autologous reconstitution of hematopoietic pre- 
cursors following ablative chemotherapy or as a target for 
gene therapy. 
Recombinant human interleukin-3 (IL-3) and interleukin- 
6 (IL-6), granulocyte-macrophage colony-stimulating factor 
(GM-CSF),  and granulocyte colony-stimulating factor (G- 
CSF) have all been shown to stimulate colony growth and 
differentiation  toward myeloid lineage from PBHP.’’.’  A re- 
cent report also has suggested a positive regulatory role for 
basic fibroblast growth factor (bFGF) on PBHP.6 An early- 
acting  hemopoietic  growth  factor  produced  by  marrow 
stromal cells, stem cell factor (SCF), has recently been iden- 
tified and determined to be the ligand for c-kit, a cell surface 
receptor with tyrosine kinase activity.’.’  Recombinant SCF 
has been shown to act in a  synergistic manner with other 
growth factors, including IL-6, IL-3, GM-CSF, G-CSF, and 
erythropoietin to induce colony formation by BM cells both 
from humans and mice.’-’’  In vivo, recombinant SCF ad- 
ministration  has been  shown  to stimulate  multiple  lym- 
phohemopoietic lineages in baboons and granulopoiesis in 
combination with G-CSF or GM-CSF in 
There is no report on the effects of recombinant SCF on 
in vitro colony growth of PBHP. Further, the effect of SCF 
in combination with bFGF and IL-6 also is not known. In 
the present study, we determined the influence of recombi- 
nant human SCF in combination with other hemopoietic 
growth factors on the growth of myeloid colonies by PBHP. 
MATERIALS AND  METHODS 
Collection and enrichment of  human peripheral blood progeni- 
tors.  For most of  the studies, enrichment of  PBHP began with a 
leukapheresis  collection of  I  to 3 X  IO9 light-density cells in preser- 
onies/l  O4 PBHP plated and from 10 to 93 large [ >  200 
cells] colonies/l  O4 PBHP plated). Furthermore, addition of 
bFGF and/or IL-6 to  the combination of optimum concen- 
trations of SCF, IL-3, GM-CSF, and G-CSF further enhanced 
colony number and size in  a dose-dependent fashion. Using 
the optimum combination of all growth factors, we  deter- 
mined that the number of myeloid colony-forming PBHP in 
whole blood was similar between individuals at about three 
colonies per milliliter whole blood. We conclude that pro- 
genitors capable of responding to  the early-acting growth 
factor, SCF, are represented in PBHP and that the number 
of circulating myeloid colony-forming PBHP is likely a reg- 
ulated parameter that may have an  important  biologic 
function. 
This is a US government work. There are no  restrictions  on 
its use. 
vative-free heparin from healthy adult donors after informed consent. 
However, for some studies where specifically indicated, 50 to  100 
mL of whole heparinized peripheral venous blood was the starting 
material for enrichment of PBHP. PBHP were enriched as follows. 
Step 1  : From leukapheresis  collection,  erythrocytes  were removed by 
ammonium chloride lysis, whereas for whole peripheral blood eryth- 
rocytes and granulocytes were removed by  collecting the light-density 
cells from a standard Ficoll-Hypaque density gradient (SD 1.077), 
(Pharmacia, Piscataway, NJ). Step 2: CD34+  cells were subjected to 
positive selection by  using an anti-CD34 monoclonal antibody MoAb 
as a commercially available kit with avidin affinity column as per 
instructions from the manufacturer (CellPro, Bothell, WA). These 
cells, representing  about a 1,000-fold final enrichment of PBHP from 
the leukapheresis (about 5,000-fold enrichment for whole blood), 
were washed twice with medium, resuspended, and then processed 
for either flow cytometric analysis or clonogenic assays. 
Cells expressing the 
surface membrane antigens CD34 and/or CD33 were identified by 
using direct-label dual-color immunofluorescence with  anti-CD33 
phycoerythrin (PE) and  anti-HPCA  2  fluorescein  isothiocyanate 
(FITC) MoAbs (Becton Dickinson, San Jose, CA). The anti-HPCA 
2 is an anti-CD34 antibody that binds to an antigenic site on CD34 
that is distinct from that recognized by  the anti-CD34 used for the 
positive selection. Cells were  simultaneously labeled with the anti- 
CD34 FITC and antLCD33 PE at 1 :  IO dilution in 200 fiL  phosphate- 
buffered saline (PBS) containing I% bovine serum albumin for  IO6 
cells for 30 minutes at 4°C and then washed three times with cold 
PBS containing 1% bovine serum albumin. Labeled cells were ana- 
lyzed using an EPICS machine (Becton Dickinson),  with filter set for 
Cytofluorometric cell surface phenotyping. 
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Fig 1.  Dual-color FACS analysis (CD34 by CD33) 
of normal peripheral blood progenitor cells before 
enrichment (left panel) and after enrichment (right 
panel). CD33 PE binding is shown on the y-axis and 
CD34 FlTC is shown on the x-axis. The data are 
displayed as a contour plot of 10,000 events. The 
percent  cells that are CD34+ and/or CD33+ in this 
Log Fluorescence CD 34-FITC  Log Fluorescence CD 34-FITC  figure are discussed in the results. 
FITC-PE dual-color fluorescence and results analyzed using Consort 
30 software (Becton Dickinson). The entire nucleated cell population 
was taken into account with the acquisition gate set to exclude only 
occasional cell aggregates and debris. Ten thousand cells were acquired 
in list mode and the frequency of cells expressing CD34 and/or CD33 
antigens was calculated as a percentage of all analyzed cells. Controls 
for the  highly enriched  PBHP consisted of the  peripheral blood 
mononuclear cells after the ammonium chloride lysis step. 
Recombinant  human  growth  factors G-CSF, 
GM-CSF, IL-3, IL-6, and bFGF were purchased from Amgen Bio- 
logicals (Thousand Oaks, CA), whereas recombinant  human SCF 
was a generous gift of Dr Kristin Zsebo (Amgen). 
The 
effects of SCF, bFGF, and/or IL-6 on colony growth of PBHP were 
determined by  addition of  these factors to a defined basal growth 
medium  (BGM). BGM  consisted of Iscove's modified Dulbecco's 
medium supplemented with 10% fetal calf serum, 4 mmol/L gluta- 
mine,  10 pmol/L mercaptoethanol, and reported plateau doses of 
IL-3 (20 ng/mL), GM-CSF (IO ng/mL), and G-CSF (1 ng/mL). En- 
riched PBHP at 104/mL  were plated at 2.5 mL/well in 0.18%  agarose 
BGM in Costar 6 well flat-bottom plates (Costar, Cambridge, MA). 
In a series of experiments, BGM was supplemented with combinations 
of SCF, bFGF, and/or IL-6 as specified. After 14 days of incubation 
at 37°C in 7% C02  humidified incubators, the agarose disk containing 
colonies from each well  were  fixed  with citrate-buffered acetone/ 
methanol fixative, dried overnight, and stained by either a Diff-quik 
stain or with a triple-stain technique using specific and nonspecific 
esterase substrates and lux01 fast blue stain to evaluate granulocytic, 
monocytic, and eosinophilic lineage cells, re~pectively.'~  Clusters of 
more than 50 cells were counted as colonies under inverted micro- 
scope and further classified as large (>200 cells) or small (1200  cells) 
colonies. In all experiments, the number of colonies on plates is ex- 
pressed as per IO4 enriched PBHP plated just after isolation. Statistical 
analysis was done by  using Student's paired t-test. The colony mor- 
phology was examined by inverted microscope before fixation and 
staining and also by  examining colonies after triple staining as de- 
scribed above. For some studies, stimulated nitrohlue tetrazolium 
reduction (NBT) was used to demonstrate production of  superoxide 
by the differentiated myeloid cells in colonies  in the semisolid agarose. 
This was done both to demonstrate viability and myeloid differen- 
tiation of cells in colonies. The test was performed by  layering over 
the agarose, 0.5  mL each of 0.2% NBT (Sigma, St Louis, MO) in 
saline and 0.4 &mL  of stimulant phorbol  12 myristate 13 acetate 
(PMA; Sigma). The NBT-positive colonies with cell-associated black 
precipitates were scored under an inverted microscope after 1 hour 
and were also easily scored after drying the agarose gels on slides as 
described earlier and counterstaining them with safranin. Colonies 
Growth factors. 
Clonal assaysfor  peripheral blood hematopoietic  progenitors. 
derived from PBHP of patients with chronic granulomatous disease, 
whose phagocytic cells are deficient in making superoxide, were used 
as a control to show the specificity of NBT reduction seen in colonies 
derived from normal donor PBHP. 
RESULTS 
Enrichment and characterizution of PBHP.  Recovery of 
cells after positive selection for CD34+  cells varied from  1.5 
to 4.5  X  IO6 from a leukapheresis collection of 250 to 300 
mL from different donors (n = 6), whereas the yield for whole 
blood was usually about 0.1 X 1  O6 for 100 mL of whole blood 
(n = 4). Dual-color fluorescence analysis was performed on 
this enriched population of PBHP after positive selection for 
CD34 and compared with mononuclear cells from the same 
leukapheresis donor before the positive selection (Fig 1).  This 
analysis showed that, compared with labeled cells before en- 
richment as the control (Fig 1, left panel), after the positive 
selection (Fig I, right panel), 70% of the cells were labeled 
with CD34. Furthermore, 60% of the PBHP-enriched cells 
were both CD34+ and CD33- (Fig  I, lower right quadrant 
of right panel), an early precursor phenotype.  Similar en- 
richment of PBHP was obtained when whole peripheral blood 
was the starting material. For the studies below, PBHP were 
derived from leukapheresis except where indicated. 
Colony  growth  of  PBHP  in  response  to growth  fac- 
tors.  SCF alone in growth medium lacking added IL-3, GM- 
CSF, and G-CSF failed to support any colony growth from 
PBHP (data not  shown). PBHP grown in complete basal 
growth medium (BGM) (IL-3, GM-CSF, G-CSF) resulted in 
the formation of well-developed myeloid colonies at 78.1 k 
3.5 colonies/104 PBHP plated (indicated as BGM in Fig 2). 
Figure 2 also shows the effect of addition of combinations of 
SCF, bFGF, and/or IL-6 to BGM on PBHP growth. Addition 
of SCF to BGM caused a highly significant (P  < 0.001) in- 
crease in the total number ofcolonies to 187.5 k 2.1 colonies/ 
IO4 enriched PBHP plated. Combinations  of SCF together 
with bFGF, IL-6, or both in BGM also increased the number 
of colonies to 228.6 k  0.6, 245.1 k  5.2, and 244.4 f  8.4 
colonies/104  PBHP plated, respectively (P  <  0.05, for all three 
compared with SCF in BGM). 
The most dramatic effect of SCF on PBHP proliferation 
was an increase in the size of colonies, as illustrated in Figs 
2 and 3. The number of large colonies increased significantly 
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Fig 2.  Colonyfonnation  by PBHP in different growth conditions. 
Colonies  were grown for 14 days in semisolid agarose culture under 
basal growth media conditions without or with the additional growth 
factors indicated. BGM refers to colony growth without additional 
factors. Where indicated, the following factors or  combination of 
factors were added to BGM (IL-6, 10 ng/mL;  bFGF,  100 ng/mL; 
SCF. 100 ng/mL). (0)  Total number of colonies; (0)  large colonies 
(>  200 cells). Each bar  2  SD  represents results from two to six 
different donors. + ,  P < .001 as compared with BGM; *,  P < .05 
as compared with SCF in BGM. 
from 9.7 f  1.8 large colonies/104 PBHP plated in BGM  to 
92.5  f  4.1  large colonies/104 PBHP plated with addition of 
SCF to BGM (P  <  0.001). This represents an increase of the 
proportion of total colonies that are large from 12% to 49%. 
When  bFGF, IL-6, or both were added in the presence of 
SCF to BGM, the number of large colonies increased to I 13.8 
f  2.5,  124.0 f  1. I, and  122.8 f  4.5  large colonies, respec- 
tively, but the proportion of  total colonies that were large 
remained at about 50%. 
Colonies derived from PBHP grown in the presence of 
SCF with  BGM  were  myeloid, with  55%  neutrophil,  5% 
monocyte, 20% eosinophil, and 20% mixed (neutrophil, eo- 
sinophil, and monocyte). The cells in all of these colonies 
were NBT positive, indicating the ability to produce super- 
oxide  upon  stimulation, a characteristic of  viable  mature 
monomyeloid cells. As a control to demonstrate the specificity 
of the NBT  results, colonies of similar number, size, and 
morphology derived  from  PBHP of  patients with chronic 
granulomatous disease of childhood were all NBT negative, 
as  would be expected for this disorder (data not shown). These 
results were consistent with  those colonies containing cells 
maturing to the myeloid phenotype. Many of the large col- 
onies contained predominantly undifferentiated cells in the 
densely populated central portion of the colony. 
Dose response 01  PBHP prolifiralion to SCF, IL-6, and 
bFGF.  In separate studies, the effects of different doses of 
SCF (25 to 200 ng/mL) added to BGM conditions on PBHP 
colony number and size were determined. The results of a 
representative experiment are shown in Fig 4A. 
Maximum effects both on colony number and size were 
obtained at a dose of IO0 ng/mL of SCF in two separate dose- 
response studies. The effects of different doses of bFGF or 
IL-6 on colony formation from PBHP in the presence of an 
optimum  amount (100 ng/mL) of SCF in BGM  were also 
studied (Fig 4B). Addition of IL-6 or bFGF to SCF increased 
both colony number  and  size in a dose-response fashion. 
peaking at  IO ng/mL of IL-6 and  100 ng/mL of bFGF. 
Determination of ,lie yield of myeloid colonies.fiom  hole 
blood.  In all the studies shown above, PBHP were enriched 
from leukapheresis units, making it impossible to determine 
yield of colonies per milliliter of whole blood. Using the op- 
timum growth conditions determined from the above studies 
(100 ng/mL SCF, 100 ng/mL bFGF. and  IO ng/mL IL-6 in 
BGM), we determined the number of myeloid colonies de- 
rived from PBHP enriched from  100 mL of whole blood as 
the starting material from four normal donors. The number 
of myeloid colonies formed were 3.6 f  2.9 colonies per mil- 
liliter of whole blood with little variation in this number be- 
tween donors. 
DISCUSSION 
There is increasing interest in the use of PBHP for autol- 
ogous reinfusion following ablative  and 
as a potential target of gene therapy. It is not firmly established 
that PBHP alone can provide permanent  long-term recon- 
stitution of all marrow elements.”.18  PBHP may or may not 
contain the earliest totipotent stem cells, and/or the number 
of such cells that can be obtained by  apheresis may be too 
low  for permanent  reconstitution.  However,  studies have 
shown that patients infused with their own stored PBHP alone 
or together with autologous stored BM  achieved earlier re- 
covery ofcirculating neutrophilic granulocytes  compared with 
patients infused with BM  Determination of in vitro 
conditions that maximize production of neutrophilic gran- 
ulocytes from PBHP would be important in developing ther- 
apies, including growth factor administration, which enhance 
this early recovery seen with  PBHP infusion. Furthermore, 
such information enhances the usefulness of PBHP as targets 
for genetic reconstitution and reinfusion in diseases affecting 
hematopoietic cells.” 
Studies have suggested some differences in the growth factor 
requirements of PBHP relative to precursors obtained from 
BM  aspirate.’ This may reflect either intrinsic differences in 
the distribution or character of individual progenitors from 
each source,” or it may reflect the effect of accessory cells. 
In the present study, we examined the growth factor require- 
ments of PBHP in the context of culture conditions that led 
to the production of myeloid cells including neutrophils. In 
particular, we  focused on the effect of SCF in combination 
with other factors. The role of accessory cells was reduced 
by enriching PBHP by positively selecting for CD34’  cells. 
SCF has been shown to be an early-acting hematopoietic 
growth factor for bone marrow precursors? The receptor for 
this factor has been identified as c-kit. which shows highest 
expression on the most primitive hematopoietic cells with 
loss during differentiation.*’ In studies of human  BM pro- 
genitors, SCF enhances colony growth and increases incor- 
poration  of  radiolabeled  thymidine  by  lineage-negative. 
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CD34+  stem cells?.'4  Although it is not known to what extent 
SCF enhances growth of later lineage progenitors, it is likely 
that effects seen with SCF reflect the known distribution of 
c-kit. In previous studies of BM  precursors, SCF functions 
as a cofactor requiring the presence of other factors such as 
IL-6.  IL-3.  GM-CSF, and/or G-CSF.'."  Furthermore,  the 
particular combination of factors present with SCF markedly 
influences both the degree of proliferation and the final dif- 
ferentiated cell types seen.'.'  '.I3 
In the present study, SCF in the presence of  IL-3, GM- 
CSF, and G-CSF increases the in vitro proliferation of  pe- 
ripheral blood myeloid progenitors. SCF increased both the 
number and size of myeloid colonies from PBHP. The num- 
Fig  3.  Appearance  of  Diff- 
quik-stained  hematopoietic col- 
onies  derived  from  PBHP-en- 
riched cells grown in semisolid 
agarose culture with BGM alone 
(A) or  in the presence of  BGM 
plus SCF (200 ng/mL) (€3)  (pho- 
tographed  at  X25 magnifica- 
tion). 
ber of colonies doubled with SCF, but the most dramatic 
effect was on the size of colonies. The number of large colonies 
increased by  about ninefold. In the present study, we  used 
200 cells as the number to define a large colony. This was a 
practical cutoff for visual counting of cells per colony. How- 
ever, the great majority of  colonies defined as large in the 
presence of SCF comprised many hundreds of cells and cor- 
responded well with what have been termed macroscopic or 
high proliferative-potential colonies in other studies. In some 
instances, a full count of cells in such large colonies indicated 
over  1,000  cells. A previous study of the effects of SCF on 
bone marrow progenitors also noted both an increase in col- 
ony number and size.24  In that study, the effect on size of 
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colonies was noted as an incidental observation and not sub- 
jected to quantitative analysis. One explanation  for these 
findings would be that SCF may induce and enhance mitosis 
of only the earliest progenitors leading to the formation of 
both more and larger colonies. This suggestion is supported 
by a published study in which lineage-negative, CD34+ BM 
cells did not proliferate unless SCF was added to other fac- 
tor~.*~  Thus, our results indicate that very early progenitors 
responding to SCF may be represented in circulating PBHP. 
However, SCF in our basal growth medium lacking added 
IL-3, GM-CSF, and G-CSF failed to support any observable 
colony growth from PBHP, indicating that SCF acts only as 
a cofactor for proliferation. Similar results have been reported 
with BM 
With  both  human  and murine hemopoietic progenitor 
cells, IL-6 acts synergistically with IL3  to support primitive 
blast colony formation,  indicating activity at a very  early 
stage of differentiati~n.’~  Furthermore, IL-6 has been shown 
to act synergistically with SCF to enhance colony growth of 
very early marrow progenitors from mice treated with 5-flu- 
orouracil.’ In a previous study, bFGF was shown to enhance 
CFU-GM colony formation from PBHP by more than 509’0.~ 
The effect of SCF on PBHP proliferation was not explored 
in that study. We therefore examined in our basal growth 
conditions the effect of  addition  of  combinations  of  IL-6, 
bFGF, and SCF. Dose-response  studies of the addition of IL- 
6 or bFGF to optimum concentrations of SCF in basal growth 
medium indicated that both bFGF and IL-6 slightly increased 
the number and size of colonies over SCF alone. Thus, in 
our study conditions, addition of bFGF and IL-6 resulted in 
some additive effect with SCF but did not demonstrate syn- 
ergy with SCF in the growth of PBHP myeloid colonies. We 
did not explore the effects of SCF combined with IL-6 and/ 
or bFGF in the absence of the added IL-3, GM-CSF, and G- 
CSF present in our basal growth conditions. The presence of 
some of these latter  factors might mask potential  synergy 
between SCF and/or IL-6 or bFGF. 
From our studies discussed above, as with many published 
studies, the focus has been on maximizing growth or puri- 
fication of PBHP from a starting source of apheresis-enriched 
lightdensity leukocytes without reference back to the number 
of circulating progenitors in whole blood. Having established 
standard conditions using SCF for optimum growth of my- 
eloid colonies from PBHP, we used these conditions to de- 
termine the number of myeloid colony-forming progenitors 
that could be derived from a standard volume of blood from 
normal donors. Estimates from other studies of the number 
of circulating CD34’  cells are 0.1% to 0.2%  of mononuclear 
cells, only a small percentage of which are capable of forming 
colonies in c~lture.~~~~’  In our study of four donors using 
whole blood as  the starting material, we found that the normal 
number  of  circulating PBHP capable of forming myeloid 
colonies  under  optimum growth  conditions  was  3.6/mL 
whole blood. Our studies also suggest that the level of cir- 
culating myeloid colony-forming progenitors  is consistent 
between individuals and likely a regulated parameter, just as 
the peripheral blood level of circulating mature neutrophils. 
These circulating myeloid colony-forming progenitors may 
have an important biologic function. 
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